An Overview of Schizotypal Personality Disorder: Etiology Treatment

Abstract

The article summarizes and analyzes some of the previous studies on schizotypal personality disorder to explain the etiology, genetic aspect such as Catechol-O-methyltransferase (COMT which is situated on chromosome 22q11) and calcium voltage-gated channel subunit alpha1 C (CACNA1C rs1006737); environmental aspect such as risky factors affecting an unnormal brain development like and psychological trauma, and chronic stress, and the treatment (Metacognitive treatment; Rumination‑Focused Cognitive Behavioral Therapy; Medication treatment) of schizotypal personality disorder are also discussed. Both methods, Metacognitive treatment, and Rumination‑Focused Cognitive Behavioral Therapy, in their respective cases, improved symptoms in schizotypal personality disorder patients. However, although research on medication treatment shows that although some medicines, like Risperidone and Haloperidol, can also improve schizotypal personality disorder symptoms, they are also accompanied by the side effects. Moreover, the analysis shows that the present research on managing schizotypal personality disorder encounters issues such as insufficient sample size and absence of repeated experiments. These results of prior studies still need further verification before they can be used in practice.